Video

Cabazitaxel for the Treatment of mCRPC: Data From the CARD Trial

Author(s):

Neal Shore, MD, FACS

Dr Shore continues his review of data on cabazitaxel for the treatment of mCRPC by highlighting efficacy data from the CARD trial and real-world data that could impact practice.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Ruben Olivares, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke
“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke
The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Expanded indication sought for niraparib plus AAP in Europe
July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke
The application is supported by data from the phase 3 AMPLITUDE trial.
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
© 2025 MJH Life Sciences

All rights reserved.